(SC1), Health, demographic change and well-being Giornata Nazionale di Lancio dei Bandi in Horizon 2020

Transcript

1 (SC1), Health, demographic change and well-being Giornata Nazionale di Lancio dei Bandi in Horizon 2020 International Research Co-Operative Group Min Salute/ISS. Ufficio 5 Internazionalizzazione e promozione infrastrutture ricerca

2

3 30 JPIAMR Membership Paesi inclusi recentemente: Egitto, India, Irlanda e Sud Africa

4 Basic Science Pre-clinical Phase I Phase II Phase III JPIAMR National Science Research Agencies EC FP / ERC IMI / ND4BB NIH / NIAID BARDA Wellcome Trust CARB-X GARDR-P EIB s InnovFin UK / China Global Innovation Fund Existed Prior 2016 Recently Launched

5 JPIAMR FUNDING (52 projects) La «Strategic Research Agenda» definisce le sei aree prioritarie dove è necessaria la ricerca in AMR. RESEARCH PROJECTS PER PILLAR NETWORKS/WORKING GROUPS PER PILLAR Environment 9% Interventions 9% Therapeutics 29% Environment 9% Interventions 9% Therapeutics 27% Diagnostics 0% Transmission 14% Transmission 49% Surveillance 4% Surveillance 27% Diagnostics 14%

6 Strategic Research Innovation Agenda: Aggiornamento scientifico in stretta collaborazione con un allineamento e co-operazione delle policies nazionali, delle risorse e della capacità di ricerca, sviluppo e Innovazione. Workshops e Guidelines da sviluppare collaborazioni tra Accademia e Industria; link con altri programmi e strutture di ricerca Europee ed Internazionali. AMR Projects Database Mappatura dei progetti di ricerca, delle linee di ricerca attive, centri/strutture di ricerca ed infrastructure. Sviluppare un interfaccia con tutti i dati della mappatura. Research Activities Lancio di tre Join Research Calls nel 2018 con un budget preliminare di circa 15 M Call 2019: indagine per valutare topic d interesse per i paesi membri in AMR (in corso). Nuovo ERANET 2019/20 : AMR Intervention Trials

7 L'esercizio di mappatura raccoglie informazioni su : AMR research funding: Dati sui finanziamenti dei progetti dai diversi bandi JPIAMR, agenzie di finanziamento nazionali e fondazioni internazionali. Per monitorare gli investimenti in progetti che vanno dalla ricerca di base, applicata e clinica, inclusi studi clinici, epidemiologici, sanitari, veterinari alla ricerca ambientale. AMR research project : Dati su progetti di ricerca sulla resistenza antimicrobica intrapresa nei 26 paesi membri, nell'ambito dei sei temi prioritari identificati nella SRA- JPIAMR. AMR research centers/units: Dati su centri di ricerca che hanno contributi significativi alla ricerca AMR. Una rete dinamica di tali unità di ricerca AMR fornirà uno stretto contatto tra il JPIAMR e la comunità scientifica e contribuirà a creare nuove capacità di ricerca nell'area dell'amr. AMR research infrastructure: La mappatura dell'infrastruttura di ricerca AMR esistente all'interno degli stati membri faciliterà la coordinazione tra database e biobanche, garantendo un efficace scambio di informazioni e campioni. AMR industry alliances and development: Verranno condotte mappature delle industrie che operano nel settore AMR e le loro esigenze specifiche per migliorare la condivisione dei dati e la comunicazione tra mondo accademico e industria.

8 Synergic activities MDR Gram positive bacteria old and new drugs Clinical trials on investigational new drugs pre registration Research Area Development of new antimicrobials Prevention and control in healthcare settings Monitoring of the appropriate use of antimicrobials New antibiotics into veterinary medicine Reduction of the use of antibiotics in animals Set-up and validation of new diagnostic tools 20 feedback (IRCCS + ISS) Typing of AMR strains AMR R 78% No Research AMR 25% Etiology of antimicrobial resistance IRCCS + ISS

9 JPIAMR 6th Call Pre-announcement New targets, compounds and tools In February of 2017 the WHO released their global priority pathogen list of antibiotic resistant bacteria (including Mycobacterium) to guide research, discovery, and development of new antibiotics. The 6 th joint call from JPIAMR is a direct response to the list supporting new targets, compounds and tools against antibiotic resistance. Publication of call January 2018 Deadline preproposals March 2018 Deadline full proposals June 2018 No. of participating countries 15 Budget Approx. 13 million Euro Project duration max 3 years Participating countries & eligibility: Consortia of eligible scientists from Belgium (FWO), Czech Republic, Egypt, Finland, France, Germany, Ireland, Israel, Italy, Latvia, Norway, Poland, Spain(MINECO), Sweden and Switzerland may apply for funding in this call.* Consortia must include a minimum of three eligible partners from at least three different countries participating in the call, and a maximum of 6 project partners (or 7 if a partner from Czech Republic, Latvia or Poland is *List is provisional additional countries may join. Final eligibility conditions will be published when call opens.

10 JPIAMR 6th Call Pre-announcement New targets, compounds and tools Drug-resistant bacteria identified by the WHO as priority pathogens PATHOGENS INCLUDED IN CALL PRIORITY 1: CRITICAL Acinetobacter baumannii, carbapenem-resistant Pseudomonas aeruginosa, carbapenem-resistant Enterobacteriaceae (including Klebsiella pneumoniae, Escherichia coli, Enterobacter spp., Serratia spp., Proteus spp., and Providencia spp, Morganella spp.), carbapenemresistant, 3rd generation cephalosporin-resistant PRIORITY 2: HIGH Enterococcus faecium, vancomycin-resistant Staphylococcus aureus, methicillin-resistant, vancomycin intermediate and resistant Helicobacter pylori, clarithromycin-resistant Campylobacter, fluoroquinolone-resistant Salmonella spp., fluoroquinolone-resistant Neisseria gonorrhoeae, 3rd generation cephalosporin-resistant, fluoroquinolone-resistant PRIORITY 3: MEDIUM Streptococcus pneumoniae, penicillin-non-susceptible Haemophilus influenzae, ampicillin-resistant Shigella spp., fluoroquinolone-resistant Studies involving multi- and extensively drug resistant Mycobacterium tuberculosis, that is also included on the WHO priority pathogen list, are eligible in this

11 JPIAMR 6th Call Pre-announcement New targets, compounds and tools TOPICS: NEW TARGETS/MECHANISMS Studies of new bacterial targets or mechanisms of resistance (examples include studies on novel enzyme or efflux pump inhibitors or others), including studies aimed at understanding and overcoming the mechanisms controlling the generation of resistance. NEW THERAPIES Studies of new compounds (including new antibiotics and alternatives). Strategies to inhibit or reduce the acquisition of resistance, such as single molecular agents effective against multiple targets as well as therapeutics that enhance immune-mediated pathogen elimination, disrupt colonisation or biofilm development, and reduce virulence. Discovery of novel therapies to overcome known antimicrobial resistance mechanisms and/or to restore susceptibility to conventional antibiotics. NEW STRATEGIES/TOOLS/ASSAYS That improve, enhance, and/or facilitate the identification or validation of new effective compounds or therapies. For optimisation of drug use, dosage and delivery of new drugs. Exploring bacterial genes, e.g. expression of latent gene clusters. NOT WITHIN THE SCOPE OF THE CALL Investigations addressing cross talk between the host and pathogen, as well as the relationship between microbes, environment and infection. Studies on bacteria not on the WHO Global priority list. Investigations on initial steps of the infection process. Investigations based on, or involving, clinical trials. Re-evaluation of existing anti-microbial compounds in the context of their combination with new, innovative targets, compounds or

12 @jpionamr

13 JPIAMR VIRTUAL RESEARCH INSTITUTE: Obiettivo: facilitare interazioni e potenziare la ricerca in AMR a livello globale. VRI Vision: ridurre il carico di AMR attraverso un approccio One Health. VRI Mission: Connecting researchers in all areas of AMR research in a One Health approach Building capacity and strengthening capability Facilitating access to scientific information and infrastructures Global reach: Bridging geographic borders Break practical barriers Increasing the visibility of the AMR issue Drive the uptake of research into policy Image licence from Adobe Stock

14